1. Home
  2. AKTX vs AEON Comparison

AKTX vs AEON Comparison

Compare AKTX & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

SELL

Current Price

$7.18

Market Cap

15.4M

Sector

Health Care

ML Signal

SELL

Logo AEON Biopharma Inc.

AEON

AEON Biopharma Inc.

HOLD

Current Price

$0.12

Market Cap

13.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AKTX
AEON
Founded
N/A
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.4M
13.0M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
AKTX
AEON
Price
$7.18
$0.12
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
★ $25.50
$1.82
AVG Volume (30 Days)
32.2K
★ 809.4K
Earning Date
11-12-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.12
$0.11
52 Week High
$29.32
$1.45

Technical Indicators

Market Signals
Indicator
AKTX
AEON
Relative Strength Index (RSI) 42.25 29.39
Support Level $5.01 N/A
Resistance Level $9.91 $0.33
Average True Range (ATR) 0.90 0.03
MACD -0.06 -0.01
Stochastic Oscillator 24.25 10.50

Price Performance

Historical Comparison
AKTX
AEON

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

About AEON AEON Biopharma Inc.

AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.

Share on Social Networks: